Kangho Suh is an Assistant Professor at the University of Pittsburgh School of Pharmacy, where he specializes in Outcomes Research and Data Science within the Department of Pharmacy and Therapeutics. He joined the faculty in the fall of 2019 after he completed his PhD from The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington. Prior to his PhD training at The CHOICE Institute, he earned his PharmD from the Ernest Mario School of Pharmacy, Rutgers University and a MS in Pharmacy Administration at The University of Texas at Austin as part of the Novartis sponsored Health Economics & Outcomes Research post-doctoral fellowship.
Kangho's research interests lie at the intersection of health economics and pharmacoepidemiology. Specifically, he aims to advance patient care and advocate the use of value-based interventions through comparative effectiveness research, exploring heterogeneity of treatment effects, and building cost-effectiveness models. He has expertise using large secondary databases, including IBM® MarketScan®, and has constructed many budget impact and cost-effectiveness models for the pharmaceutical industry and Washington Research Foundation. Kangho is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and Society for Medical Decision Making (SMDM).
Hansen R, Suh K, Serbin M, Yonan C, Sullivan SD. Cost-effectiveness analysis of opicapone and entacapone in Parkinson’s Disease: An incremental OFF-time model in the United States. Presented at the Academy of Managed Care Pharmacy Nexus Annual Meeting, National Harbor, MD, October 29-November 1, 2019.
Suh K, Basu A, Branch K, Carlson JJ. Examining the cost-effectiveness of empirical passive personalization with P2Y12 inhibitors in patients with acute coronary syndrome. Presented at the Society for Medical Decision Making 41st Annual Meeting, Portland, OR, October 20-23, 2019.
Hansen R, Williamson T, Cameron J, Suh K, Carlson JJ, Sullivan SD. Budget impact analysis of larotrectinib for 8 tumors in the United States. Presented at the International Society of Pharmacoeconomics and Outcomes Research 24th Annual Meeting, New Orleans, LA, May 18-22, 2019.
Suh K, Basu A, Yeung K, Bansal A, Garrison LP, Carlson JJ. Concept analysis on cures for illnesses with high disease burden. Presented at the International Society of Pharmacoeconomics and Outcomes Research 22nd Annual Meeting, Boston MA, May 20-24, 2017.
Carlson JJ, Bansal A, Suh K, Yeung K, Garrison LP, Basu A. Health impact framework for cures and high impact medical technologies. Presented at the International Society of Pharmacoeconomics and Outcomes Research 22nd Annual Meeting, Boston MA, May 20-24, 2017.
Suh K, Carlson JJ, Garrison LP. Projecting the potential cost-effectiveness of ocrelizumab versus standard care in primary progressive multiple sclerosis patients under alternative pricing scenarios. Presented at the International Society of Pharmacoeconomics and Outcomes Research 21st Annual International Meeting, Washington, DC, May 21-25, 2016